Home / Market News / $RFL
benzinga Corporate Catalyst Impact 95/100 ● negative

Why Is Rafael Stock Falling Wednesday?

Sep 30, 2026, 5:39 PM UTC · Primary ticker $RFL

Rafael Holdings Inc. announced that its pivotal Phase 3 TransportNPC study for Trappsol Cyclo in Niemann-Pick Disease Type C (NPC) missed its overall primary endpoint, despite showing a directionally favorable treatment effect. This negative clinical trial outcome has led to a significant drop in the company's stock price.

Rafael Holdings Inc. (RFL) experienced a sharp decline in its stock price due to the announcement that its key Phase 3 clinical trial for Trappsol Cyclo, targeting Niemann-Pick Disease Type C (NPC), failed to meet its overall primary endpoint. While a prespecified subgroup analysis showed statistical significance, the overall miss is a major setback for the drug's approval prospects and the company's valuation, especially for a micro-cap biotech heavily reliant on this single asset. This news significantly impacts RFL shareholders in the short term, as evidenced by the 37.89% drop. The long-term implications depend on whether the FDA will consider the subgroup analysis sufficient for regulatory filing, which the company still plans for Q4 2026, but the path forward is now much riskier.

$RFL negative Phase 3 trial missed primary endpoint
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.